What is the official website of Actavis plc (now Allergan) ?

The official website of Actavis plc (now Allergan) is http://www.allergan.com.

What is Actavis plc (now Allergan)'s cybersecurity risk score?

Actavis plc (now Allergan) has an AI-generated cybersecurity risk score of 835 out of 1000, indicating a Good security posture according to Rankiteo's assessment.

How many security incidents has Actavis plc (now Allergan) experienced?

According to Rankiteo, Actavis plc (now Allergan) currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Actavis plc (now Allergan) been affected by any supply chain cyber incidents ?

According to Rankiteo, Actavis plc (now Allergan) has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Actavis plc (now Allergan) have SOC 2 Type 1 certification ?

According to Rankiteo, Actavis plc (now Allergan) is not certified under SOC 2 Type 1.

Does Actavis plc (now Allergan) have SOC 2 Type 2 certification ?

According to Rankiteo, Actavis plc (now Allergan) does not hold a SOC 2 Type 2 certification.

Does Actavis plc (now Allergan) comply with GDPR ?

According to Rankiteo, Actavis plc (now Allergan) is not listed as GDPR compliant.

Does Actavis plc (now Allergan) have PCI DSS certification ?

According to Rankiteo, Actavis plc (now Allergan) does not currently maintain PCI DSS compliance.

Does Actavis plc (now Allergan) comply with HIPAA ?

According to Rankiteo, Actavis plc (now Allergan) is not compliant with HIPAA regulations.

Does Actavis plc (now Allergan) have ISO 27001 certification ?

According to Rankiteo,Actavis plc (now Allergan) is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Actavis plc (now Allergan) operate in ?

Actavis plc (now Allergan) operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Actavis plc (now Allergan) have ?

Actavis plc (now Allergan) employs approximately 1,503 people worldwide.

Does Actavis plc (now Allergan) own any subsidiaries ?

Actavis plc (now Allergan) presently has no subsidiaries across any sectors.

How many LinkedIn followers does Actavis plc (now Allergan) have ?

Actavis plc (now Allergan)'s official LinkedIn profile has approximately followers.

What is the NAICS classification code for Actavis plc (now Allergan) ?

Actavis plc (now Allergan) is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Actavis plc (now Allergan) have a Crunchbase profile ?

No, Actavis plc (now Allergan) does not have a profile on Crunchbase.

Does Actavis plc (now Allergan) have a LinkedIn profile ?

Yes, Actavis plc (now Allergan) maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/actavis-inc-.

How many cybersecurity incidents has Actavis plc (now Allergan) experienced ?

As of August 31, 2026, Rankiteo reports that Actavis plc (now Allergan) has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Actavis plc (now Allergan) have ?

Actavis plc (now Allergan) has an estimated 5,747 peer or competitor companies worldwide.

What types of cybersecurity incidents has Actavis plc (now Allergan) faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Vulnerability.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Boost Score +25 with badge (5 left)

835

/1000

Good

860

/1000

Very Good

Actavis plc (now Allergan) Vendor Cyber Rating & Cyber Score

allergan.com

Add Your Compliance Badge

We would like to invite you to follow our new Allergan page at https://www.linkedin.com/company/allergan?trk=top_nav_home

AP A.I CyberSecurity Scoring

Scoring History

Actavis plc (now Allergan) CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

AbbVie

Vulnerability

100

4/2026

EGAABB177565877...

Actavis plc (now Al...

Breach

100

6/2023

ABB0473723

Loading…

A.I.

AP Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for AP

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Actavis plc (now Allergan) in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Actavis plc (now Allergan) in 2026.

Incident Types AP vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Actavis plc (now Allergan) in 2026.

Incident History - AP (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Actavis plc (now Allergan) Subsidiaries

AP

Pharmaceutical Manufacturing

Website: http://www.allergan.com

Company Size: 2-10 employees

AllerganPharmaceutical Manufacturing

AbbViePharmaceutical Manufacturing

OncologyPharmaceutical Manufacturing

Allergan AestheticsPharmaceutical Manufacturing

Pharmacyclics, an AbbVie CompanyPharmaceutical Manufacturing

AbbVieEyetoEyePharmaceutical Manufacturing

Allergan Data LabsIT Services and IT Consulting

ImmunologyPharmaceutical Manufacturing

NeurosciencePharmaceutical Manufacturing

Allergan Eye CarePharmaceutical Manufacturing

AbbVieEyetoEyePharmaceutical Manufacturing

AbbVie Contract ManufacturingPharmaceutical Manufacturing

VirologyPharmaceutical Manufacturing

Eye CarePharmaceutical Manufacturing

Actavis (now Allergan)Pharmaceutical Manufacturing

Forest Laboratories (now Allergan)Pharmaceutical Manufacturing

Forest ResearchPharmaceutical Manufacturing

SkinMedica Inc., An Allergan CompanyPharmaceutical Manufacturing

India Pvt. LtdPharmaceutical Manufacturing

Loading…

Actavis plc (now Allergan) Similar Companies

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Novartis

novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Loading…

NEWS

Actavis plc (now Allergan) CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 17, 2015 07:00 AM

Actavis Completes Acquisition of Allergan

Actavis PLC on Tuesday completed its acquisition of Allergan Inc., now valued at $70.5 billion, closing the biggest deal from 2014.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-82592

SUMMARY

A vulnerability was detected in D-Link DIR-825M 1.1.8. This affects the function sub_46725C of the file /boafrm/formDiskFormat of the component Disk Formatting Handler Endpoint. The manipulation of the argument partition results in stack-based buffer overflow. The attack can be executed remotely. The exploit is now public and may be used.

Published

Date2026-08-30

Updated

Date2026-08-30

RISK INFORMATION (Score: 9.9)

cvss2

Base Score: 9.0

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 9.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

3.1

REFERENCES

CVE-2026-82591

SUMMARY

A security vulnerability has been detected in Open Asset Import Library Assimp up to 6.0.2. The impacted element is the function MD5Importer::MakeDataUnique of the file code/AssetLib/MD5/MD5Loader.cpp. The manipulation of the argument iNewIndex leads to heap-based buffer overflow. The attack can only be performed from a local environment. The identifier of the patch is bf9dabb617c46e5133dac65cca6bff177917afcb. Applying a patch is the recommended action to fix this issue.

Published

Date2026-08-30

Updated

Date2026-08-30

RISK INFORMATION (Score: 5.3)

cvss2

Base Score: 4.3

Complexity: LOW

AV:L/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 4.8

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

1.8

REFERENCES

CVE-2026-82590

SUMMARY

A weakness has been identified in Open5GS up to 2.7.7. The affected element is the function smf_nudm_sdm_handle_get of the file src/smf/nudm-handler.c of the component SMF. Executing a manipulation of the argument preemptCap can lead to reachable assertion. The attack may be launched remotely. Upgrading to version 2.8.0 is sufficient to fix this issue. This patch is called 4554405f29bffd7562abedbee63484825bd90cd5. You should upgrade the affected component.

Published

Date2026-08-30

Updated

Date2026-08-30

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 4.0

Complexity: LOW

AV:N/AC:L/Au:S/C:N/I:N/A:P

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:L

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-82589

SUMMARY

A security flaw has been discovered in Open5GS up to 2.7.7. Impacted is the function amf_namf_comm_handle_n1_n2_message_transfer of the file src/amf/namf-handler.c of the component N1-N2 Message Handler. Performing a manipulation of the argument N1N2MessageTransferReqData.n2InfoContainer.smInfo.n2InfoContent.ngapIeType results in denial of service. The attack may be initiated remotely. The exploit has been released to the public and may be used for attacks. Upgrading to version 2.8.0 is recommended to address this issue. The patch is named abf8a836564b966b5141110fc25ed413c4f17522. It is advisable to upgrade the affected component.

Published

Date2026-08-30

Updated

Date2026-08-30

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 4.0

Complexity: LOW

AV:N/AC:L/Au:S/C:N/I:N/A:P

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-82588

SUMMARY

A vulnerability was identified in Open5GS up to 2.7.7. This issue affects some unknown processing of the file src/amf/namf-handler.c of the component Transfer Endpoint. Such manipulation leads to null pointer dereference. The attack can be launched remotely. Upgrading to version 2.8.0 is capable of addressing this issue. The name of the patch is abf8a836564b966b5141110fc25ed413c4f17522. Upgrading the affected component is advised.

Published

Date2026-08-30

Updated

Date2026-08-30

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 4.0

Complexity: LOW

AV:N/AC:L/Au:S/C:N/I:N/A:P

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:L

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…